Atrial tachyarrhythmia recurred in 39 patients treated with Boston Scientific’s Farapulse PFA device, while 53 people had recurrence in the Medtronic cryoablation group.

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

The SINGLE SHOT CHAMPION study increases momentum for PFA as a first-line option for pulmonary vein isolation, say experts.

Boston Scientific (NYSE: BSX) announced new study findings demonstrating the superiority of its Farapulse pulsed field ...

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...

Boston Scientific continues to successfully expand its operations across various geographies outside the United States.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Home Depot, ...

The stock rose during the quarter after the company reported better-than-expected organic growth and raised its earnings guidance, driven by continued strength in FARAPULSE, its atrial ...

Boston Scientific has disclosed its largest CEO pay package since 2009 with $21.4 million in total compensation for Boston Scientific President, CEO and Chair Mike Mahoney in 2024. That’s the first ...

PFA offers the best means to achieve that with the least risk of complications.” Revolutionizing AFib Treatment: Discover the New Farapulse Technology Play Revolutionizing AFib Treatment: Discover the ...

Steven Mickelsen, the electrophysiologist who founded Farapulse before it was sold to Boston Scientific in 2021, is taking pulsed field ablation into new territory with the development of a device ...